Jill Maureen Cooper, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Jill Maureen Cooper’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C21707 · Cancelled
Licence status: Cancelled · since 1960 · University of Pittsburgh School of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Washington ARNP.AP.30007850-NPAdvanced Registered Nurse Practitioner License · since 2007 · expires 2012-03-17ExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$53,001
Medicare paid this office $53,001 for 369 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 165 | $17,315 | $77 |
| Short return visit (20+ min) | 179 | $12,649 | $56 |
| Long return visit (40+ min) | 67 | $9,468 | $114 |
| New patient visit (45+ min) | 53 | $4,954 | $93 |
| New patient visit (60+ min) | 31 | $3,911 | $126 |
See all 7 services
| Return visit (30+ min) | 165 | $17,315 | $77 |
| Short return visit (20+ min) | 179 | $12,649 | $56 |
| Long return visit (40+ min) | 67 | $9,468 | $114 |
| New patient visit (45+ min) | 53 | $4,954 | $93 |
| New patient visit (60+ min) | 31 | $3,911 | $126 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 43 | $2,326 | $54 |
| Short return visit | 62 | $2,001 | $32 |
Who their Medicare patients are
369 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 19% · Women 59% · Also on Medicaid 15% · Health risk score 1.91. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 73% · Cancer 39% · Chronic kidney disease 37% · Diabetes 31% · Coronary heart disease 28% · Depression 22% · Heart failure 21% · Atrial fibrillation 21% · COPD 16% · Stroke 8% · Dementia 5%.
The office billed $225,816, Medicare allowed $69,633 and paid $53,001; for 728 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 369 | 728 | 76 | 1.91 | $225,816 | $53,001 |
| 2023 | 279 | 572 | 76 | 1.88 | $161,045 | $39,638 |
| 2022 | 220 | 438 | 75 | 1.73 | $89,486 | $27,389 |
| 2021 | 218 | 344 | 75 | 2.24 | $70,048 | $23,886 |
| 2020 | 206 | 272 | 76 | 2.90 | $111,064 | $12,439 |
| 2019 | 54 | 57 | 74 | 2.33 | $36,520 | $2,484 |
| 2018 | 14 | 21 | 65 | 1.88 | $4,601 | $872 |
| 2017 | 50 | 59 | 69 | 1.92 | $11,454 | $1,771 |
| 2016 | 245 | 399 | 69 | 2.01 | $73,776 | $14,306 |
| 2015 | 169 | 245 | 69 | 2.02 | $47,593 | $9,066 |
| 2014 | 87 | 99 | 68 | 1.57 | $18,450 | $3,853 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 158 | $16,342 | $69 |
| Short return visit (20+ min) | 122 | $8,449 | $49 |
| Long return visit (40+ min) | 56 | $8,115 | $110 |
| New patient visit (60+ min) | 23 | $3,073 | $134 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 38 | $2,166 | $54 |
| New patient visit (45+ min) | 12 | $1,129 | $94 |
| Short return visit | 13 | $355 | $25 |
2022: 4 services
| Return visit (30+ min) | 140 | $14,886 | $72 |
| Short return visit (20+ min) | 102 | $7,217 | $47 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 35 | $2,003 | $57 |
| Long return visit (40+ min) | 17 | $1,688 | $99 |
2021: 4 services
| Return visit (30+ min) | 131 | $12,286 | $73 |
| Long return visit (40+ min) | 33 | $4,226 | $114 |
| Short return visit (20+ min) | 62 | $4,208 | $50 |
| Short return visit | 19 | $518 | $25 |
2020: 4 services
| Return visit (30+ min) | 86 | $6,476 | $60 |
| Short return visit (20+ min) | 70 | $2,968 | $40 |
| Long return visit (40+ min) | 13 | $1,146 | $82 |
| Short return visit | 39 | $806 | $20 |
2019: 2 services
| Short return visit (20+ min) | 19 | $897 | $47 |
| Return visit (30+ min) | 12 | $815 | $68 |
2017: 2 services
| Short return visit (20+ min) | 31 | $739 | $21 |
| Return visit (30+ min) | 12 | $590 | $45 |
2016: 3 services
| Short return visit (20+ min) | 196 | $8,772 | $31 |
| Return visit (30+ min) | 70 | $5,005 | $55 |
| Short return visit | 22 | $381 | $17 |
2015: 3 services
| Short return visit (20+ min) | 112 | $4,344 | $32 |
| Return visit (30+ min) | 63 | $4,343 | $51 |
| Short return visit | 20 | $313 | $16 |
2014: 3 services
| Short return visit (20+ min) | 45 | $1,788 | $36 |
| Return visit (30+ min) | 24 | $1,625 | $56 |
| Short return visit | 18 | $341 | $18 |
Drugs they prescribed that Part D paid
$2,178,840
Pharmacies billed $2,178,840 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 6% of their Part D prescriptions (82 of 1,389) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%. Long-acting opioids: 21% of their opioid prescriptions.
1,059 generic and fewer than 11 brand-name prescriptions · $2,178,840 in drug cost · 66 antibiotic prescriptions to 48 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenalidomide | 22 | $250,400 | $11,382 |
| Verzenio | 12 | $209,229 | $17,436 |
| Jakafi | 11 | $183,988 | $16,726 |
| Eliquis | 168 | $164,064 | $977 |
| Xarelto | 23 | $23,353 | $1,015 |
See all 36 drugs
| Lenalidomide | 22 | $250,400 | $11,382 |
| Verzenio | 12 | $209,229 | $17,436 |
| Jakafi | 11 | $183,988 | $16,726 |
| Eliquis | 168 | $164,064 | $977 |
| Xarelto | 23 | $23,353 | $1,015 |
| Anastrozole | 91 | $2,111 | $23 |
| Megestrol Acetate | 23 | $2,062 | $90 |
| Exemestane | 14 | $1,555 | $111 |
| Tamoxifen Citrate | 49 | $1,369 | $28 |
| Hydroxyurea | 25 | $940 | $38 |
| Gabapentin | 67 | $829 | $12 |
| Morphine Sulfate Er | 15 | $754 | $50 |
| Pantoprazole | 47 | $602 | $13 |
| Mirtazapine | 17 | $552 | $32 |
| Acyclovir | 35 | $542 | $15 |
| Prochlorperazine Maleate | 28 | $472 | $17 |
| Hydrocortisone | 23 | $451 | $20 |
| Nystatin | 16 | $355 | $22 |
| Dexamethasone | 21 | $345 | $16 |
| Hydrocodone-Acetaminophen | 21 | $340 | $16 |
| Omeprazole | 20 | $296 | $15 |
| Morphine Sulfate | 12 | $272 | $23 |
| Nitrofurantoin Mono-Macro | 16 | $213 | $13 |
| Losartan | 14 | $197 | $14 |
| Sulfamethoxazole-Trimethoprim | 16 | $180 | $11 |
| Ondansetron | 26 | $174 | $7 |
| Folic Acid | 18 | $152 | $8 |
| Levothyroxine | 11 | $148 | $13 |
| Prednisone | 22 | $104 | $5 |
| Hydrochlorothiazide | 11 | $88 | $8 |
| Allopurinol | 20 | $74 | $4 |
| Lorazepam | 16 | $74 | $5 |
| Sertraline | 15 | $60 | $4 |
| Tramadol | 16 | $59 | $4 |
| Escitalopram | 13 | $29 | $2 |
| Meloxicam | 12 | $26 | $2 |
Year by year
| 2024 | 1,389 | 307 | 6% (82) | None | $2,178,840 |
| 2023 | 776 | 197 | 7% (57) | None | $1,272,247 |
| 2022 | 324 | 113 | 12% (39) | None | $113,516 |
| 2021 | 282 | 110 | 7% (20) | 10% | $126,772 |
| 2020 | 120 | 75 | 10% (12) | 9% | $6,823 |
| 2019 | 70 | 37 | None | None | $2,148 |
| 2018 | 85 | 41 | None | None | $1,526 |
| 2017 | 603 | 167 | 6% (33) | 18% | $608,112 |
| 2016 | 1,748 | 250 | 6% (100) | None | $1,772,258 |
| 2015 | 1,374 | 199 | 7% (93) | None | $1,022,794 |
| 2014 | 1,118 | 177 | 6% (71) | 14% | $300,010 |
| 2013 | 829 | 138 | 5% (38) | None | $223,258 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Eliquis | 90 | $94,445 | $1,049 |
| Xarelto | 12 | $13,933 | $1,161 |
| Potassium Chloride | 17 | $2,565 | $151 |
| Morphine Sulfate Er | 18 | $1,323 | $74 |
| Gabapentin | 48 | $1,086 | $23 |
| Anastrozole | 41 | $1,041 | $25 |
| Tamoxifen Citrate | 26 | $775 | $30 |
| Ondansetron | 26 | $634 | $24 |
| Mirtazapine | 15 | $433 | $29 |
| Famotidine | 23 | $275 | $12 |
| Dexamethasone | 14 | $239 | $17 |
| Hydrocodone-Acetaminophen | 11 | $210 | $19 |
| Pantoprazole | 15 | $155 | $10 |
| Tramadol | 12 | $105 | $9 |
| Furosemide | 14 | $67 | $5 |
| Prednisone | 13 | $62 | $5 |
| Folic Acid | 18 | $38 | $2 |
2022: 4 drugs
| Eliquis | 12 | $13,292 | $1,108 |
| Anastrozole | 26 | $889 | $34 |
| Morphine Sulfate Er | 19 | $820 | $43 |
| Gabapentin | 19 | $387 | $20 |
2021: 6 drugs
| Anastrozole | 64 | $1,422 | $22 |
| Dexamethasone | 13 | $355 | $27 |
| Prochlorperazine Maleate | 12 | $246 | $20 |
| Ondansetron | 16 | $193 | $12 |
| Sulfamethoxazole-Trimethoprim | 11 | $108 | $10 |
| Gabapentin | 14 | $94 | $7 |
2018: 1 drug
| Anastrozole | 16 | $203 | $13 |
2017: 11 drugs
| Ibrance | 19 | $218,646 | $11,508 |
| Mekinist | 13 | $135,704 | $10,439 |
| Tafinlar | 13 | $124,990 | $9,615 |
| Exemestane | 14 | $7,542 | $539 |
| Tamoxifen Citrate | 74 | $3,008 | $41 |
| Anastrozole | 109 | $1,859 | $17 |
| Gabapentin | 50 | $1,095 | $22 |
| Letrozole | 22 | $195 | $9 |
| Pantoprazole | 19 | $169 | $9 |
| Alendronate | 14 | $103 | $7 |
| Zolpidem | 17 | $50 | $3 |
2016: 37 drugs
| Ibrance | 88 | $925,569 | $10,518 |
| Afinitor | 34 | $411,796 | $12,112 |
| Mekinist | 16 | $54,358 | $3,397 |
| Tafinlar | 16 | $49,384 | $3,086 |
| Lyrica | 28 | $13,253 | $473 |
| Exemestane | 24 | $7,216 | $301 |
| Tamoxifen Citrate | 203 | $6,521 | $32 |
| Celecoxib | 22 | $4,325 | $197 |
| Anastrozole | 243 | $3,371 | $14 |
| Raloxifene | 14 | $2,433 | $174 |
| Venlafaxine Hcl Er | 50 | $1,952 | $39 |
| Gabapentin | 109 | $1,692 | $16 |
| Letrozole | 78 | $1,077 | $14 |
| Potassium Chloride | 29 | $1,063 | $37 |
| Fentanyl | 14 | $978 | $70 |
| Ondansetron | 41 | $957 | $23 |
| Hydrocodone-Acetaminophen | 22 | $930 | $42 |
| Acyclovir | 21 | $742 | $35 |
| Diphenoxylate-Atropine | 12 | $572 | $48 |
| Morphine Sulfate Er | 14 | $517 | $37 |
| Pantoprazole | 44 | $419 | $10 |
| Levetiracetam | 22 | $369 | $17 |
| Klor-Con 10 | 21 | $369 | $18 |
| Dexamethasone | 18 | $330 | $18 |
| Lidocaine-Prilocaine | 11 | $287 | $26 |
| Warfarin | 11 | $197 | $18 |
| Trazodone | 32 | $190 | $6 |
| Omeprazole | 21 | $188 | $9 |
| Prochlorperazine Maleate | 14 | $168 | $12 |
| Alendronate | 24 | $164 | $7 |
| Lorazepam | 21 | $157 | $7 |
| Levothyroxine | 11 | $125 | $11 |
| Zolpidem | 11 | $76 | $7 |
| Atenolol | 12 | $66 | $6 |
| Tramadol | 12 | $61 | $5 |
| Meloxicam | 11 | $40 | $4 |
| Hydrochlorothiazide | 12 | $26 | $2 |
2015: 29 drugs
| Afinitor | 53 | $567,430 | $10,706 |
| Gleevec | 15 | $135,607 | $9,040 |
| Welchol | 21 | $8,982 | $428 |
| Exemestane | 22 | $7,461 | $339 |
| Lyrica | 16 | $7,409 | $463 |
| Tamoxifen Citrate | 166 | $5,921 | $36 |
| Nexium | 12 | $4,872 | $406 |
| Anastrozole | 207 | $2,843 | $14 |
| Raloxifene | 18 | $2,715 | $151 |
| Celecoxib | 12 | $2,462 | $205 |
| Letrozole | 70 | $1,899 | $27 |
| Gabapentin | 97 | $1,214 | $13 |
| Hydrocodone-Acetaminophen | 30 | $1,109 | $37 |
| Fentanyl | 16 | $999 | $62 |
| Venlafaxine Hcl Er | 19 | $760 | $40 |
| Ondansetron | 24 | $739 | $31 |
| Morphine Sulfate Er | 13 | $671 | $52 |
| Potassium Chloride | 28 | $595 | $21 |
| Dexamethasone | 31 | $535 | $17 |
| Acyclovir | 25 | $452 | $18 |
| Omeprazole | 35 | $315 | $9 |
| Zolpidem | 13 | $238 | $18 |
| Prochlorperazine Maleate | 20 | $237 | $12 |
| Pantoprazole | 19 | $179 | $9 |
| Prednisone | 20 | $177 | $9 |
| Alendronate | 25 | $157 | $6 |
| Tramadol | 12 | $149 | $12 |
| Lorazepam | 21 | $144 | $7 |
| Trazodone | 15 | $63 | $4 |
2014: 23 drugs
| Afinitor | 15 | $144,805 | $9,654 |
| Lyrica | 19 | $7,334 | $386 |
| Anastrozole | 231 | $6,375 | $28 |
| Celebrex | 13 | $3,945 | $303 |
| Tamoxifen Citrate | 113 | $3,705 | $33 |
| Exemestane | 11 | $3,578 | $325 |
| Letrozole | 44 | $1,381 | $31 |
| Gabapentin | 77 | $1,236 | $16 |
| Acyclovir | 47 | $945 | $20 |
| Hydrocodone-Acetaminophen | 28 | $633 | $23 |
| Ondansetron | 23 | $592 | $26 |
| Potassium Chloride | 23 | $528 | $23 |
| Pantoprazole | 40 | $483 | $12 |
| Venlafaxine Hcl Er | 22 | $379 | $17 |
| Omeprazole | 20 | $324 | $16 |
| Dexamethasone | 22 | $302 | $14 |
| Diphenoxylate-Atropine | 12 | $284 | $24 |
| Tramadol | 16 | $223 | $14 |
| Alendronate | 24 | $205 | $9 |
| Lorazepam | 22 | $143 | $7 |
| Escitalopram | 13 | $115 | $9 |
| Citalopram Hbr | 12 | $86 | $7 |
| Zolpidem | 14 | $78 | $6 |
2013: 20 drugs
| Afinitor | 12 | $98,447 | $8,204 |
| Exemestane | 11 | $8,729 | $794 |
| Anastrozole | 184 | $6,094 | $33 |
| Tamoxifen Citrate | 66 | $1,544 | $23 |
| Letrozole | 27 | $1,389 | $51 |
| Pantoprazole | 33 | $1,176 | $36 |
| Gabapentin | 51 | $1,170 | $23 |
| Acyclovir | 37 | $927 | $25 |
| Potassium Chloride | 27 | $648 | $24 |
| Venlafaxine Hcl Er | 17 | $414 | $24 |
| Nystatin | 13 | $328 | $25 |
| Hydrocodone-Acetaminophen | 15 | $310 | $21 |
| Dexamethasone | 21 | $287 | $14 |
| Omeprazole | 17 | $286 | $17 |
| Prochlorperazine Maleate | 13 | $192 | $15 |
| Zolpidem | 26 | $160 | $6 |
| Alendronate | 15 | $154 | $10 |
| Lorazepam | 18 | $107 | $6 |
| Citalopram Hbr | 11 | $97 | $9 |
| Metformin | 11 | $33 | $3 |
Money from drug and device companies
$1,923 in 2025
| 2025 | 28 | 79 | None | $1,923 |
| 2024 | 22 | 47 | None | $1,318 |
| 2023 | 28 | 62 | $1,000 | $2,841 |
| 2022 | 19 | 54 | None | $1,154 |
| 2021 | 13 | 33 | None | $825 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Daiichi Sankyo | Injectafer | $376 | 18 payments
|
| Celgene | Reblozyl | $224 | 9 payments
|
| Merck Sharp & Dohme | Keytruda | $182 | 7 payments
|
| Janssen Biotech | Darzalex | $149 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $149 | 6 payments
|
| Abbvie | Imbruvica | $75 | 3 payments
|
See all 78 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-15 | Enhertu | $24 |
| Adc Therapeutics America | Meals · 2025-12-11 | Zynlonta | $35 |
| Deciphera Pharmaceuticals | Meals · 2025-11-21 | Qinlock | $29 |
| GlaxoSmithKline | Meals · 2025-11-14 | Blenrep | $25 |
| Puma Biotechnology | Meals · 2025-11-11 | Nerlynx | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-06 | Iclusig | $25 |
| Abbvie | Meals · 2025-10-30 | Elahere | $26 |
| Celgene | Meals · 2025-10-24 | Reblozyl | $28 |
| Daiichi Sankyo | Meals · 2025-10-23 | Enhertu | $19 |
| Gilead Sciences | Meals · 2025-10-22 | Trodelvy | $26 |
| Pharmacosmos Therapeutics | Meals · 2025-10-21 | Monoferric | $15 |
| Caris MPI | Meals · 2025-10-09 | Mi Cancer Seek | $21 |
| Merck Sharp & Dohme | Meals · 2025-10-08 | Keytruda | $29 |
| Daiichi Sankyo | Meals · 2025-10-02 | Datroway | $22 |
| Abbvie | Meals · 2025-09-19 | Venclexta | $21 |
| Agios Pharmaceuticals | Meals · 2025-09-18 | Pyrukynd | $22 |
| GlaxoSmithKline | Meals · 2025-09-16 | Ojjaara | $29 |
| Geron | Meals · 2025-09-10 | Rytelo | $32 |
| Adc Therapeutics America | Meals · 2025-09-09 | Zynlonta | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-05 | Enhertu | $34 |
| Adaptive Biotechnologies | Meals · 2025-08-28 | Clonoseq | $18 |
| Kite Pharma | Meals · 2025-08-27 | Yescarta | $22 |
| Lilly USA | Meals · 2025-08-25 | Cyramza | $27 |
| Celgene | Meals · 2025-08-19 | Breyanzi | $3 |
| Celgene | Meals · 2025-08-19 | Reblozyl | $31 |
| Array Biopharma | Meals · 2025-08-15 | Braftovi | $26 |
| Kyowa Kirin | Meals · 2025-08-13 | Poteligeo | $29 |
| GlaxoSmithKline | Meals · 2025-08-08 | Nucala | $19 |
| Merck Sharp & Dohme | Meals · 2025-08-05 | Keytruda | $28 |
| Daiichi Sankyo | Meals · 2025-07-29 | Injectafer | $5 |
| Daiichi Sankyo | Meals · 2025-07-29 | Injectafer | $9 |
| Daiichi Sankyo | Meals · 2025-07-25 | Injectafer | $20 |
| Novartis Pharmaceuticals | Meals · 2025-07-17 | Fabhalta | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-15 | Opdivo | $21 |
| Janssen Biotech | Education · 2025-07-09 | Darzalex | $50 |
| Celgene | Meals · 2025-07-02 | Opdivo | $18 |
| Celgene | Meals · 2025-06-25 | Reblozyl | $30 |
| Janssen Biotech | Meals · 2025-06-20 | Darzalex | $44 |
| Eisai | Meals · 2025-06-19 | Lenvima | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-17 | Stivarga | $17 |
| Array Biopharma | Meals · 2025-06-13 | Lorbrena | $33 |
| Daiichi Sankyo | Meals · 2025-06-11 | Injectafer | $17 |
| Daiichi Sankyo | Meals · 2025-06-06 | Injectafer | $5 |
| Daiichi Sankyo | Meals · 2025-06-06 | Injectafer | $14 |
| Daiichi Sankyo | Meals · 2025-05-23 | Injectafer | $12 |
| Daiichi Sankyo | Meals · 2025-05-21 | Injectafer | $133 |
| Kite Pharma | Meals · 2025-05-12 | Yescarta | $16 |
| Daiichi Sankyo | Meals · 2025-04-25 | Injectafer | $13 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-23 | Ninlaro | $15 |
| Pharmacosmos Therapeutics | Meals · 2025-04-16 | Monoferric | $25 |
| SpringWorks Therapeutics | Meals · 2025-04-15 | Ogsiveo | $20 |
| Merck Sharp & Dohme | Meals · 2025-04-10 | Keytruda | $30 |
| Genentech USA | Meals · 2025-04-09 | Ocrevus Zunovo | $23 |
| Daiichi Sankyo | Meals · 2025-04-08 | Injectafer | $21 |
| Celgene | Meals · 2025-04-04 | Opdivo | $35 |
| Janssen Biotech | Meals · 2025-03-25 | Darzalex | $21 |
| Celgene | Meals · 2025-03-11 | Reblozyl | $26 |
| Merck Sharp & Dohme | Meals · 2025-03-06 | Keytruda | $23 |
| Daiichi Sankyo | Meals · 2025-03-05 | Injectafer | $7 |
| Daiichi Sankyo | Meals · 2025-03-05 | Injectafer | $27 |
| Merck Sharp & Dohme | Meals · 2025-02-27 | Keytruda | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-25 | Enhertu | $34 |
| Abbvie | Meals · 2025-02-18 | Imbruvica | $28 |
| Janssen Biotech | Meals · 2025-02-15 | Rybrevant | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-11 | Enhertu | $34 |
| Novartis Pharmaceuticals | Meals · 2025-02-06 | Fabhalta | $27 |
| Celgene | Meals · 2025-02-04 | Opdivo | $34 |
| Daiichi Sankyo | Meals · 2025-01-31 | Injectafer | $19 |
| Daiichi Sankyo | Meals · 2025-01-31 | Injectafer | $6 |
| Kyowa Kirin | Meals · 2025-01-29 | Poteligeo | $27 |
| Daiichi Sankyo | Meals · 2025-01-28 | Enhertu | $19 |
| Daiichi Sankyo | Meals · 2025-01-28 | Enhertu | $9 |
| Merck Sharp & Dohme | Meals · 2025-01-28 | Keytruda | $23 |
| Sobi | Meals · 2025-01-17 | Vonjo | $40 |
| Merck Sharp & Dohme | Meals · 2025-01-16 | Keytruda | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-15 | Lynparza | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-14 | Lynparza | $5 |
| Celgene | Meals · 2025-01-09 | Reblozyl | $18 |
See earlier years (2024, 2023, 2022, 2021)
2024: $1,318
| Janssen Biotech | Darzalex | $344 | 6 payments
|
| Celgene | Reblozyl | $132 | 6 payments
|
| Daiichi Sankyo | Enhertu | $97 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $88 | 4 payments
|
| Abbvie | Imbruvica | $68 | 3 payments
|
| Array Biopharma | Xalkori | $56 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $55 | 2 payments
|
| Eisai | Lenvima | $55 | 2 payments
|
| Gilead Sciences | None | $52 | 2 payments
|
| Aadi Bioscience | Fyarro | $44 | 2 payments
|
| Genentech USA | Lunsumio | $42 | 2 payments
|
| Astellas Pharma US | Padcev | $40 | 2 payments
|
| GlaxoSmithKline | Ojjaara | $31 | 1 payment
|
| Lilly USA | Cyramza | $29 | 1 payment
|
| Coherus Biosciences | Udenyca | $26 | 1 payment
|
| Ipsen Biopharmaceuticals | Onivyde | $25 | 1 payment
|
| Novartis Pharmaceuticals | Fabhalta | $25 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $24 | 1 payment
|
| Kite Pharma | Yescarta | $23 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $23 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Iclusig | $20 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $20 | 1 payment
|
2023: $2,841
| G1 Therapeutics | Cosela | $1,324 | 3 payments
|
| Janssen Biotech | Tecvayli | $210 | 6 payments
|
| Amgen | Lumakras | $196 | 4 payments
|
| Daiichi Sankyo | Injectafer | $111 | 5 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $104 | 4 payments
|
| Pfizer | Xtandi | $89 | 5 payments
|
| Eisai | Lenvima | $85 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $80 | 4 payments
|
| Regeneron Healthcare Solutions | Libtayo | $59 | 2 payments
|
| Celgene | Reblozyl | $54 | 2 payments
|
| Kyowa Kirin | Poteligeo | $49 | 2 payments
|
| CTI BioPharma | Vonjo | $46 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $42 | 2 payments
|
| Gilead Sciences | Trodelvy | $38 | 2 payments
|
| Novartis Pharmaceuticals | Kisqali | $32 | 2 payments
|
| Genentech USA | Lunsumio | $31 | 1 payment
|
| Seagen | Tukysa | $29 | 1 payment
|
| Astellas Pharma US | Padcev | $28 | 1 payment
|
| CSL Behring | Idelvion | $28 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $27 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $26 | 1 payment
|
| Mirati Therapeutics | Krazati | $26 | 1 payment
|
| Taiho Oncology | Lonsurf | $25 | 1 payment
|
| Stemline Therapeutics | Orserdu | $23 | 1 payment
|
| TerSera Therapeutics | Zoladex | $22 | 1 payment
|
| Apellis Pharmaceuticals | Empaveli | $21 | 1 payment
|
| Kite Pharma | Yescarta | $19 | 1 payment
|
| PharmaEssentia USA | Besremi | $19 | 1 payment
|
2022: $1,154
| Janssen Biotech | Darzalex | $241 | 8 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $171 | 3 payments
|
| Daiichi Sankyo | Injectafer | $160 | 10 payments
|
| Incyte | Monjuvi | $99 | 1 payment
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $71 | 3 payments
|
| Seagen | Tivdak | $67 | 3 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $47 | 2 payments
|
| Myriad Genetic Laboratories | Precisetumor | $44 | 2 payments
|
| GlaxoSmithKline | Zejula | $41 | 2 payments
|
| Gilead Sciences | Trodelvy | $35 | 2 payments
|
| Array Biopharma | Braftovi | $32 | 1 payment
|
| Kyowa Kirin | Poteligeo | $25 | 1 payment
|
| TerSera Therapeutics | Zoladex | $24 | 1 payment
|
| CTI BioPharma | Vonjo | $23 | 1 payment
|
| Taiho Oncology | Lonsurf | $17 | 1 payment
|
| MorphoSys US | Monjuvi | $15 | 1 payment
|
| Novartis Pharmaceuticals | Kisqali | $15 | 1 payment
|
| Celgene | None | $14 | 1 payment
|
| Genentech USA | Phesgo | $12 | 1 payment
|
2021: $825
| Pharmacyclics LLC An AbbVie | Imbruvica | $281 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $80 | 2 payments
|
| Daiichi Sankyo | Injectafer | $79 | 4 payments
|
| GlaxoSmithKline | Blenrep | $67 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | None | $64 | 3 payments
|
| Celgene | None | $48 | 2 payments
|
| Pfizer | Lorbrena | $45 | 3 payments
|
| Seagen | Tukysa | $43 | 2 payments
|
| Janssen Biotech | Rybrevant | $34 | 1 payment
|
| ADC Therapeutics America | None | $25 | 1 payment
|
| Taiho Oncology | Inqovi | $22 | 1 payment
|
| Kyowa Kirin | Poteligeo | $21 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $16 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1376722520
- Licence
- CA 21707, WA AP30007850California C21707: CancelledWashington ARNP.AP.30007850-NP: Expired
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LA2200X (363LA2200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-10-24
- NPI last updated
- 2025-12-30
- NPI record certified
- 2025-12-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 210 Oaks Ave, Monrovia, CA, 91016